glp-1 weight loss drugs tirzepatide semaglutide Drugs: 6 Things We've Learned About Their Effects Understanding GLP-1s and Their Role

[PMID: 36213159] PubMed record related to this compound for laboratory literature review

At the same time, clinicians should reinforce the substantial benefits of treatment, including improved glycemic control, weight reduction, and cardiovascular protection

The conditions that most commonly support eligibility include: Obesity (BMI 30, or 27 with at least one comorbidity such as hypertension, sleep apnea, or cardiovascular disease) Type 2 diabetes or prediabetes Insulin resistance with clinical documentation Metabolic syndrome (clinically diagnosed) Polycystic Metabolic Ovarian Syndrome (PMOS) and related hormonal disorders Non-alcoholic fatty liver disease (NAFLD/MASLD) Perimenopause-related metabolic dysfunction with documented hormonal changes GLP-1 receptor agonists including semaglutide, tirzepatide, and retatrutide are the most commonly used peptides in metabolic care today

Link Tejera-Segura B, et al

Start with a $49 virtual visit.